Fight against patent for hepatitis C drug that can cost €55,000 

Facing cancer, young adults blog and draw their way through fears 
April 11, 2017
US cancer deaths are decreasing, study finds
April 12, 2017
Show all

Fight against patent for hepatitis C drug that can cost €55,000 

Charities aim to increase access to medications that treat hepatitis C in Europe

A GROUP of charities, led by Médecins Sans Frontières, is fighting to have a drug’s patent revoked by the European Patent Office. Sofosbuvir can cure hepatitis C in just three months, but costs up to €55,000 for a course of treatment.

The drug’s patent is held by pharmaceuticals firm Gilead of Foster City, California, giving the company a monopoly over the drug in Europe.

“There are 80 million people in the world with hepatitis C, but only 5.4 million have access to sofosbuvir,” says Yuan Qiong Hu, legal adviser for MSF’s patent challenge. “Revocation of the patent would be a key step towards making generics available.”

Source: Fight against patent for hepatitis C drug that can cost €55,000 | New Scientist

Read Full Article: Fight against patent for hepatitis C drug that can cost €55,000 | New Scientist

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.